基于种族分层的IB期非小细胞肺癌的术后辅助化疗生存分析

相关实验视频

Updated: Sep 9, 2025

04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.3K

Shaowei Xin^1,2, Tao Wang², Xiaodi Qi¹

¹Department of Thoracic Surgery, 962 Hospital of the Joint Logistics Support Force, Harbin, Heilongjiang, China.

ANZ journal of surgery

|September 4, 2025

概括

在非小细胞肺癌 (NSCLC) 阶段的白人患者中,辅助化疗改善了生存率. 然而,对于非白人患者来说,它没有显著的生存益处,这表明需要特定种族的治疗策略.

科学领域:

癌症学
癌症研究
临床试验和流行病学

背景情况:

辅助化疗对IB期非小细胞肺癌 (NSCLC) 存活率的作用仍有争议.
现有的数据主要反映了高加索人群,因此治疗有效性的种族差异尚不清楚.

研究的目的:

对IB期NSCLC的辅助化疗有效性的种族差异进行调查.
确定辅助化疗是否能在不同种族群体中提供生存益处.

主要方法:

从SEER数据库 (2010-2018) 中分析了7458名T2N0M0期NSCLC患者.
患者分为白人 (6076) 和非白人 (1382) 组.
通过卡普兰- 梅尔和考克斯回归评估的总生存率.

主要成果:

接受辅助化疗的白人患者在PSM前后均有显著改善的生存状况 (p < 0. 001).
在非白人患者中没有显著的生存差异 (p > 0. 05),除了差异化小组的有限益处 (p = 0. 008).
多变量考克斯分析发现辅助化疗在白人患者中是独立的OS预测因子 (p < 0. 001),而非非白人患者 (p = 0. 184).

结论:

对于IB期NSCLC的辅助化疗的有效性存在显著的种族差异.
对于IB期NSCLC的治疗决定,应考虑患者的种族背景,以获得最佳的结果.
需要进一步研究以了解这些种族差异背后的生物学和临床因素.

关键词:

辅助性化疗非小细胞肺癌种族异质性生存分析

相关概念视频

01:21

Cancer Survival Analysis

448

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

448

01:20

Comparing the Survival Analysis of Two or More Groups

280

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...

280

01:15

Assumptions of Survival Analysis

196

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.

196

01:20

Actuarial Approach

132

The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...

132

01:25

Statistical Methods for Analyzing Epidemiological Data

530

Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:

530

01:24

Kaplan-Meier Approach

258

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

258